Trial Profile

A phase 2 study for acute management of the symptoms of premenstrual dysphoric disorder (PMDD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PH 80 (Primary)
Indications Premenstrual dysphoric disorder
Focus Therapeutic Use
Sponsors Pherin Pharmaceuticals

Most Recent Events

09 Apr 2024 According to a Vistagen Biopharmaceuticals media release, data from this study will be presented at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.
14 Sep 2023 New trial record
12 Sep 2023 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com